Q2 2026 13F · SEC CIK 1643354

Lion Point Capital, LP

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $20.9M
Reported positions: 35
Top holdings a year, 3 yrs: +26.2%
Assets under management: $480.6M

Lion Point Capital, LP is a hedge fund that reported 35 positions worth $20.9M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Cue Biopharma Inc (CUE, 8.0%), Praxis Precision Medicines I (PRAX, 7.1%), Moonlake Immunotherapeutics (MLTX, 6.3%). A portfolio copying its top holdings returned 26.2% a year over the last 3 years, against 20.4% for the S&P 500.

Lion Point Capital, LP holdings all 35 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Lion Point Capital, LP 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
CUECue Biopharma Inc	8.0%	New	52,928	—	$1.7M
PRAXPraxis Precision Medicines I	7.1%	8.6%	4,450	+0.0%	$1.5M
MLTXMoonlake Immunotherapeutics	6.3%	7.5%	67,500	+0.0%	$1.3M
FENCFennec Pharmaceuticals Inc	5.8%	4.1%	112,434	+0.0%	$1.2M
RPRXRoyalty Pharma PLC	5.7%	6.1%	21,400	+0.0%	$1.2M
CMPSCompass Pathways PLC	5.4%	2.6%	80,000	+0.0%	$1.1M
MISTMilestone Pharmaceuticals in	5.3%	5.8%	820,000	+0.0%	$1.1M
BNTCBenitec Biopharma Inc	4.0%	3.9%	62,000	+0.0%	$830K
SNDXSyndax Pharmaceuticals Inc	3.8%	5.0%	36,000	+0.0%	$787K
BHVNBiohaven Ltd	3.7%	2.6%	51,700	+0.0%	$769K
GERNGeron Corp	3.5%	5.1%	578,000	+0.0%	$740K
QUREUniqure NV	3.2%	1.4%	14,700	+0.0%	$677K
ARDXArdelyx Inc	3.1%	4.6%	128,650	+0.0%	$656K
LNTHLantheus Hldgs Inc	2.9%	2.5%	5,500	+0.0%	$610K
IRONDisc Medicine Inc	2.8%	3.1%	8,100	+0.0%	$592K
SRPTSarepta Therapeutics Inc	2.5%	3.7%	28,500	+0.0%	$512K
HUMAHumacyte, Inc.	2.4%	2.4%	650,000	+0.0%	$507K
KURAKura Oncology Inc	2.4%	2.2%	46,000	+0.0%	$505K
VTRSViatris Inc	2.1%	2.2%	27,700	+0.0%	$440K
DYNDyne Therapeutics Inc	1.9%	1.9%	18,000	+0.0%	$400K
BBIOBridgebio Pharma Inc	1.8%	2.2%	5,000	+0.0%	$372K
EWTXEdgewise Therapeutics Inc	1.8%	1.7%	9,100	+0.0%	$370K
PCRXPacira Biosciences Inc	1.6%	1.8%	13,500	+0.0%	$342K
RGNXRegenxbio Inc	1.5%	1.3%	26,600	+0.0%	$319K
RCKTRocket Pharmaceuticals Inc	1.4%	1.8%	86,000	+0.0%	$294K
JANXJanux Therapeutics Inc	1.4%	1.6%	19,000	+0.0%	$292K
MLYSMineralys Therapeutics Inc	1.4%	1.7%	10,500	+0.0%	$283K
GHRSGh Research PLC	1.3%	0.9%	10,200	+0.0%	$274K
MCRBSeres Therapeutics Inc	1.2%	1.7%	31,570	+0.0%	$249K
BRKSAzenta Inc	1.2%	1.2%	9,700	+0.0%	$248K
JSPRJasper Therapeutics Inc	0.9%	2.4%	465,000	+0.0%	$196K
INVAInnoviva Inc	0.9%	1.1%	8,200	+0.0%	$186K
IPHAInnate Pharma S A	0.7%	0.6%	81,151	+0.0%	$149K
ARQTArcutis Biotherapeutics Inc	0.7%	0.7%	5,250	+0.0%	$138K
85209E208Spruce Biosciences Inc	0.3%	0.4%	1,000	+0.0%	$54K

What Lion Point Capital, LP bought and sold in Q2 2026, against Q1 2026.

New positions

CUE Cue Biopharma Inc8.0% of 13F

Added to

No position grew by more than 5%.

Reduced

No position shrank by more than 5%.

Sold out

CUE Cue Biopharma Incwas 3.0%

Share counts compared with the Q1 2026 13F; a split also changes share counts.

How the holdings did against the S&P 500.

1 year: +37.3% /yr; S&P 500 +20.1%
3 years: +26.2% /yr; S&P 500 +20.4%
5 years: +22.4% /yr; S&P 500 +13.5%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$20.9M	35
Q1 2026	$16.7M	35
Q4 2025	$19.3M	39
Q3 2025	$17.6M	27
Q2 2025	$14.7M	19
Q1 2025	$15.7M	21
Q4 2024	$19.1M	19
Q3 2024	$24.9M	23
Q2 2024	$31.9M	24
Q1 2024	$51.7M	27
Q4 2023	$111.3M	27
Q3 2023	$108.6M	26

Questions about Lion Point Capital, LP's portfolio

What stocks does Lion Point Capital, LP own?

Lion Point Capital, LP's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 35 positions worth $20.9M. The largest are Cue Biopharma Inc (CUE) at 8.0%, Praxis Precision Medicines I (PRAX) at 7.1%, Moonlake Immunotherapeutics (MLTX) at 6.3%, Fennec Pharmaceuticals Inc (FENC) at 5.8% and Royalty Pharma PLC (RPRX) at 5.7%.

What did Lion Point Capital, LP buy last quarter?

In Q2 2026, Lion Point Capital, LP added a new position in Cue Biopharma Inc (CUE), compared with its Q1 2026 filing.

What did Lion Point Capital, LP sell last quarter?

In Q2 2026, Lion Point Capital, LP sold all of Cue Biopharma Inc (CUE), compared with its Q1 2026 filing.

How has Lion Point Capital, LP's portfolio performed?

A portfolio copying Lion Point Capital, LP's 20 largest 13F holdings each quarter, from the day each filing was public, returned +26.2% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +37.3% against +20.1%. Over 5 years: +22.4% a year against +13.5%.

When is Lion Point Capital, LP's next 13F filing due?

13F filings are due 45 days after each quarter ends. Lion Point Capital, LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Lion Point Capital, LP manage?

Lion Point Capital, LP reported $480.6M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $20.9M.